ArticleFrontiers in medicine2026
Machine learning-based prediction of herbal medicine response in functional dyspepsia: protocol for a randomized, assessor-blinded, multicenter trial.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The purpose of this study is to evaluate the predictive accuracy of a machine learning-based herbal medicine response prediction algorithm in patients with functional dyspepsia (FD). In a preliminary clinical study, the algorithm was developed using the XGBoost regressor framework to predict the relative effect sizes of three commonly prescribed herbal formulations- Methods: This study is a randomized, assessor-blinded, parallel-group, open-label, multicenter clinical trial. A total of 100 patients with FD will be recruited from two Korean medical hospitals and randomly assigned to either the ACCORD group ( Outcomes: The primary outcome will be gastrointestinal symptom score. Secondary outcomes will include total dyspepsia symptom score, adequate relief of dyspepsia, overall treatment effect, visual analog scale score, functional dyspepsia-related quality of life, and pattern identification questionnaire results. Exploratory outcomes will include blood and fecal metabolome analysis, fecal and salivary microbiota profiling, and measurements obtained using Korean medicine diagnostic devices (heart rate variability, tongue, pulse, and abdominal diagnosis). Conclusion: Integrating a machine learning-based prediction system into treatment strategies for FD may enhance clinical practice and support the broader adoption of artificial intelligence-driven approaches in personalized medicine. Clinical trial registration: Clinical Research information Service (registration number: KCT0010587) and Open Science Framework (https://osf.io/2ecz8).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.